EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates

Fernanda Rodrigues de Lima, Jéssika de Oliveira Viana iD, Aleff Cruz de Castro, Rodrigo Cristiano, Marcia Alberton Perelló, Alexia de Matos Czeczot, Cristiano Valim Bizarro, Pablo Machado, Luiz Augusto Basso, Claudio Gabriel Lima-Junior, Valnês da Silva Rodrigues-Junior, Karen Cacilda Weber iD

Chemical Biology & Drug Design · 2025-07 · 106 (1)

DOI: 10.1111/cbdd.70152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 01.07.2025. Verfasst von Fernanda Rodrigues de Lima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-Graduação em Química, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil. Hauptthemen laut MEDLINE: Antitubercular Agents, Isatin, Mycobacterium tuberculosis, Spiro Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Apoio à Pesquisa do Estado da Paraíba, Banco Nacional de Desenvolvimento Econômico e Social.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a major global health threat, exacerbated by multidrug‐resistant Mycobacterium tuberculosis (MTB) strains. The development of new anti‐TB agents is crucial. In this study, 17 isatin derivatives synthesized by our research group were evaluated for their in vitro activity against MTB strains and the two most potent compounds were assessed for cytotoxicity. Additionally, molecular docking was performed against 22 MTB protein targets to explore possible mechanisms of action, and ADMET predictions were used to determine pharmacokinetic and pharmacodynamic suitability. Also, we investigated the activity of A15, A16, and A17 against two genetically characterized multidrug‐resistant clinical isolates (PT‐12 and PT‐20). As a result, the compounds A16 and A17 exhibited the highest anti‐TB activity (MIC = 10 μM for both). Inverse molecular docking indicated the enzyme enoyl‐[acyl‐carrier‐protein] reductase as a potential biological target. Cytotoxicity assays confirmed that A16 and A17 were non‐toxic, and ADMET predictions indicated suitable drug‐like properties for anti‐TB therapy. Notably, A16 and A17 showed inhibitory effects against drug‐resistant MTB isolates, with minimum inhibitory concentrations (MICs) ranging from 10 to 20 μM, suggesting their potential to overcome resistance mechanisms linked to mutations in katG and rpoB. These findings highlight A16 and A17 as promising candidates for anti‐TB agents, particularly against multidrug‐resistant strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsIsatinMycobacterium tuberculosisSpiro CompoundsHumansBacterial ProteinsCell SurvivalMicrobial Sensitivity TestsMolecular Docking SimulationOxindolesSpirooxindolesTuberculosis, Multidrug-ResistantComputer Simulation

Stichwörter der Autor:innen

antituberculosis agentsinverse dockingisatin‐derivativesmultidrug‐resistant Mycobacterium tuberculosisspirooxindoles

Substanzen

Antitubercular AgentsBacterial ProteinsIsatinOxindolesSpiro CompoundsSpirooxindoles

Autor:innen und Institutionen

  • Programa de Pós-Graduação em Química, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil.
  • National Institute of Science and Technology on Molecular Sciences-INCT-CiMol, João Pessoa, Brazil.
  • Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
  • Programa de Pós-Graduação em Biologia Celular e Molecular, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, Brazil.
  • Programa de Pós-Graduação em Medicina e Ciências da Saúde, PUCRS, Porto Alegre, Brazil.
  • Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil.

ORCID-Profile: Jéssika de Oliveira Viana, Karen Cacilda Weber

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Apoio à Pesquisa do Estado da Paraíba
  • Banco Nacional de Desenvolvimento Econômico e Social
  • Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul

Zitieren

APA

de Lima, F. R., de Oliveira Viana, J., de Castro, A. C., Cristiano, R., Perelló, M. A., Czeczot, A. M., Bizarro, C. V., Machado, P., Basso, L. A., Lima-Junior, C. G., Rodrigues-Junior, V. D. S., & Weber, K. C. (2025). In Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates. Chemical Biology & Drug Design, 106(1). https://doi.org/10.1111/cbdd.70152

Vancouver

de Lima FR, de Oliveira Viana J, de Castro AC, Cristiano R, Perelló MA, Czeczot AM, et al. In Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates. Chemical Biology & Drug Design. 2025;106(1). doi:10.1111/cbdd.70152

BibTeX
@article{deLima2025,
  author = {de Lima, Fernanda Rodrigues and de Oliveira Viana, Jéssika and de Castro, Aleff Cruz and Cristiano, Rodrigo and Perelló, Marcia Alberton and Czeczot, Alexia de Matos and Bizarro, Cristiano Valim and Machado, Pablo and Basso, Luiz Augusto and Lima-Junior, Claudio Gabriel and Rodrigues-Junior, Valnês da Silva and Weber, Karen Cacilda},
  title = {In Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  volume = {106},
  number = {1},
  doi = {10.1111/cbdd.70152}
}
Kostenlos starten →